Rohtak News Magazine

Parainfluenza Virus Infection Pipeline as Novel and Extensive 5+ Therapies Likely to Enter in the Treatment Domain

 Breaking News
  • No posts were found

Parainfluenza Virus Infection Pipeline as Novel and Extensive 5+ Therapies Likely to Enter in the Treatment Domain

December 08
22:28 2022
Parainfluenza Virus Infection Pipeline as Novel and Extensive 5+ Therapies Likely to Enter in the Treatment Domain

DelveInsight’s, “Parainfluenza Virus Infection Pipeline Insight, 2022,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Parainfluenza Virus Infection pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key takeaways from the Parainfluenza Virus Infection Pipeline Report

  • DelveInsight’s Parainfluenza Virus Infection Pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Parainfluenza Virus Infection.
  • The leading Parainfluenza Virus Infection Companies are working include AlloVir, Ansun Biopharma, Moderna Therapeutics, and others.
  • PromisingParainfluenza Virus Infection Pipeline therapies include mRNA-1653, MEDI-534, DAS181 dry powder, formulation F02, DAS181-F02 Dry Powder in Bulk, artus Influenza A/B RT-PCR Test, and others.
  • The Parainfluenza Virus Infection Companies and academics are working to assess challenges and seek opportunities that could influence R&D Parainfluenza Virus Infection. The therapies under development are focused on novel approaches to treat/improve Parainfluenza Virus Infection.

 

Recent Developmental Activities in the Parainfluenza Virus Infection Pipeline

  • Oplunofusp (DAS181) is a recombinant sialidase protein that can cleave sialic acid, the virus receptors located on the surface of epithelial cells lining the human respiratory track.  Treatment with DAS181 can block virus entry into respiratory epithelial cells, thus preventing viral infection and spreading.  DAS181 is a host-directed therapeutic that has demonstrated anti-viral activity against sialic-acid dependent viruses such as parainfluenza, metapneumovirus, enterovirus 68 and influenza, including strains of influenza that have developed resistance to other drugs and pandemic strains, such as H7N9, H5N1, and H1N1 and many others.

 

Request a sample and discover the recent advances in Parainfluenza Virus Infection Treatment Drugs @ Parainfluenza Virus Infection Pipeline Outlook Report

 

Parainfluenza Virus Infection Overview

The human parainfluenza virus (HPIV) is an enveloped, negative-sense, single-stranded RNA virus that belongs to the family of Paramyxoviridae. HPIV can cause both upper respiratory tract infection (URTI) and lower respiratory tract infection (LRTI) in children, usually under the age of 5, immunocompromised adults, and the elderly. Although HPIV demonstrated a resemblance to the influenza virus, HPIV is unique and can be easily and simply separated from the myxoviruses (influenza virus). The parainfluenza virus shared some characteristics with the influenza virus, including few antigenic sites, as well as their poor growth in embryonated eggs. 

The pathogenesis of the parainfluenza virus consists of the host immune response and viral mechanisms. The attachment and the fusion of the virus to the host cell are mediated by the virus surface proteins hemagglutinin-neuraminidase (HN) and fusion glycoproteins (F) with the sialic acid residues on the surface of host epithelial cells respectively. Transcription and maturation are mediated by the actin and the cytoskeleton, which also play a role in the movement of viral glycoproteins towards the surface of the host cells.

 

Parainfluenza Virus Infection Pipeline Report

In the Parainfluenza Virus Infection Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Parainfluenza Virus Infection collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Parainfluenza Virus Infection Emerging Drugs Profile

  • Oplunofusp: Ansun Biopharma

 

Parainfluenza Virus Infection Pipeline Therapeutics Assessment

There are approx. 5+ key companies which are developing the therapies Parainfluenza Virus Infection. The companies which have their Parainfluenza Virus Infection drug candidates in the most advanced stage, i.e phase III include Ansun Biopharma.

 

Get an overview of the Parainfluenza Virus Infection Pipeline Report @ Parainfluenza Virus Infection Ongoing Clinical Trials Analysis

 

Scope of the Parainfluenza Virus Infection Pipeline Report

  • Coverage- Global
  • Parainfluenza Virus Infection Companies- AlloVir, Ansun Biopharma, Moderna Therapeutics, and others.
  • Parainfluenza Virus Infection Pipeline therapies- mRNA-1653, MEDI-534, DAS181 dry powder, formulation F02, DAS181-F02 Dry Powder in Bulk, artus Influenza A/B RT-PCR Test, and others.
  • Parainfluenza Virus Infection Emerging Therapies, Unmet Needs, Analyst Views

 

Table of Content

  1. Introduction
  2. Parainfluenza Virus Infection Executive Summary
  3. Parainfluenza Virus Infection: Overview
  4. Parainfluenza Virus Infection Pipeline Therapeutics
  5. Parainfluenza Virus Infection Therapeutic Assessment
  6. Parainfluenza Virus Infection– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Oplunofusp: Ansun Biopharma
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Drug name: Company name
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I/II)
  14. ALVR 106: AlloVir
  15. Drug profiles in the detailed report…..
  16. Early Stage Products (Phase I)
  17. mRNA 1653: Moderna Therapeutics
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Parainfluenza Virus Infection Key Companies
  21. Parainfluenza Virus Infection Key Products
  22. Parainfluenza Virus Infection- Unmet Needs
  23. Parainfluenza Virus Infection- Market Drivers and Barriers
  24. Parainfluenza Virus Infection- Future Perspectives and Conclusion
  25. Parainfluenza Virus Infection Analyst Views
  26. Parainfluenza Virus Infection Key Companies
  27. Appendix

 

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Parainfluenza Virus Infection drugs?
  • How many Parainfluenza Virus Infection drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Parainfluenza Virus Infection?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Parainfluenza Virus Infection therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Parainfluenza Virus Infection and their status?
  • What are the key designations that have been granted to the emerging drugs?

 

For further information on the Parainfluenza Virus Infection Pipeline therapeutics, reach out to Parainfluenza Virus Infection Treatment Landscape

Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09193216187
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/

Related Articles